Volume 4, Issue 2, December 2020, Page: 39-44
Kidney Tumors in Adult: Epidemiological, Clinical, Histopathological, Therapeutic and Progressive Aspects
Modou Ndiaye, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Abdoulaye Ndiath, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Babacar Sine, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Alioune Sarr, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Ousmane Sow, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Omar Gaye, Urology-Andrology Department, Idrissa Pouye Hospital, Dakar, Senegal
Ndiaga Seck Ndour, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Aboubacar Traoré, Urology-Andrology Department, De la Paix Hospital, Ziguinchor, Senegal
Cyrille Zé Ondo, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Amath Thiam, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Ngor Mack Thiam, Urology-Andrology Department, Idrissa Pouye Hospital, Dakar, Senegal
El Hadji Malick Diaw, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Ousmane Dabo, Urology-Andrology Department, Idrissa Pouye Hospital, Dakar, Senegal
Boubacar Fall, Urology-Andrology Department, De la Paix Hospital, Ziguinchor, Senegal
Babacar Diao, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Papa Ahmed Fall, Urology-Andrology Department, Dala Diam Hospital, Dakar, Senegal
Alain Khassim Ndoye, Urology-Andrology Department, Aristide Le Dantec Hospital, Dakar, Senegal
Received: May 6, 2020;       Accepted: May 25, 2020;       Published: Jun. 8, 2020
DOI: 10.11648/j.ijcu.20200402.11      View  53      Downloads  26
Abstract
Objective: To study the epidemiological, diagnostic and therapeutic profile of kidney tumors in adults over the past five years. Patients and methods: This was a retrospective, descriptive and analytical Study from the 1st of January 2014 to 31st of December 2018. All patients aged 18 years or older hospitalized, followed or operated in the service for a kidney tumor were included in the serie. The parameters studied were: epidemiological, clinical and paraclinical aspects, TNM stage (2017), treatment, histological type, evolution and survival. The calculation of survival rate was done with SPSS IBM statistics 24. Results: sixty-seven patients were included. The average annual incidence was 13. The average age of the patients was 49.6±15.6 years. The sex-ratio was 1.2. Hypertension, smoking and obesity were the main risk factors found. The average size of the tumor was 7.7±4.40 cm. The left kidney location was more frequent. Thirteen patients (20%) had a localized tumor in the kidney, twenty patients (31%) had locally advanced cancer and thirty two patients (49%) had metastasized cancer. Forty-seven patients (70%) had surgical treatment, including five patients with an anti-angiogenic adjuvant therapy. Twelve (17.9%) patients had an anti-angiogenic therapy only. Clear cell carcinoma was the most common histology type. The overall survival (OS) rate for cancer patients at 2 years was 22% for surgical treatment, 8% for medical treatment. Conclusion: this work reveals that adult kidney cancer affects young adult and is discovered at advanced stages without any significant change in the epidemiological and clinical profile of these cancers during the two decades.
Keywords
Tumor, Cancer, Kidney, Nephrectomy, Anti-angiogenic
To cite this article
Modou Ndiaye, Abdoulaye Ndiath, Babacar Sine, Alioune Sarr, Ousmane Sow, Omar Gaye, Ndiaga Seck Ndour, Aboubacar Traoré, Cyrille Zé Ondo, Amath Thiam, Ngor Mack Thiam, El Hadji Malick Diaw, Ousmane Dabo, Boubacar Fall, Babacar Diao, Papa Ahmed Fall, Alain Khassim Ndoye, Kidney Tumors in Adult: Epidemiological, Clinical, Histopathological, Therapeutic and Progressive Aspects, International Journal of Clinical Urology. Vol. 4, No. 2, 2020, pp. 39-44. doi: 10.11648/j.ijcu.20200402.11
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Coulange C, Rambeaud J J. Cancer du rein de l’adulte Rapport-Congrès AFU 1997. Prog Urol 1997; 5.
[2]
Honde M, Koffi K, Ette-dieng E, Boka MB, Effi B A, Troh E et al. Aspects épidémiologie et caractéristiques histologies du cancer du rein de l’adulte A ABIDJAN - COTE D’IVOIRE Méd Afr Noire; 1998, 45: 449-450.
[3]
Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
[4]
Reaume M N, Basappa N S, Wood L, Kapoor A, Bjarnason G A, Blais N, et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Can Urol Asso Journal. 2017; 11 (10): 310-20.
[5]
Skolarus T A, Serrano M F, Grubb R L, Katz M D, Bullock T L Effect of reclassification on the incidence of benign and malignant renal tumors. J Uro 2010; 183: 455-459
[6]
Fall B, Diao B, Sow Y, Sarr A, Thiam A, Fall P A et al. Le cancer du rein de l’adulte au Sénégal: aspects épidémiologiques et cliniques actuels et évolution du profil sur les deux dernières décennies. Prog urol 2011; 21: 521—526.
[7]
Bowa K, Kachimba J S, Labib M A, Mudenda V, Chikwenya M. The Pattern of Urological Cancers in Zambia. AFJU. 2009; 15 (2): 84-87.
[8]
Benjelloun M, Nouri A, Ghannam Y, Karmouni T, El Khader K, Koutani A et al. Le cancer du rein chez l’adulte. Etude rétrospective à propos de 155 cas. AFJU. 2009; 15 (4): 268-277.
[9]
Lynch C F, Cohen M B. Urinary system. Cancer 1995; 75 (1): 316-329.
[10]
Muscat J E, Hoffmann D, Wynder E L. The epidemiology of renal cell carcinoma. A second look. Cancer. 1995; 75 (10): 2552-2557.
[11]
Black R J, Bray F, Ferlay J, Parkin D M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1977; 33: 1075–1107.
[12]
Ouattara A, Hodonou R, Avakoudjo J, Cisse D, Zango B, Gandaho B et al. Épidémiologie des cancers urologiques au Centre national hospitalier universitaire Hubert Koutoukou Maga Cotonou, Bénin. Analyse d’une série hospitalière de 158 cas. Prog Urol 2012; 22 (5): 261-265.
[13]
Soulié M, Coloby P, Irani J, Lebret T, Patard J J, Pfister C et al. Recommandations de bonnes pratiques cliniques 2013 du CCAFU: Diagnostic, traitement et suivi des cancers urologiques chez l’homme et la femme. Prog Urol. 2013; 23 (2): 51-54.
[14]
Argani P, Perlman E J, Breslow N E, Browning N E, Green D M, D’Anngio G J et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Centre. Am. J. Surg. Pathol. 2000; 24: 4-18.
[15]
Bouya P A, Lomina D. Diagnostic du cancer du rein de l'adulte. Carcinologie Pratique en Afrique 2004; 6 (1): 6-18.
[16]
Motzer R J, Hutson T E, Tomczak P, Michaelson M D, Bukowski R M, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356 (2): 115-124.
[17]
Flohr H, Breull W. Effect of etafenone on total and regional myocardial blood flow. Arzneimittelforschung. 1975; 25 (9): 1400-1403.
[18]
Helenon O, Denys A, Rotkopf L. Imagerie du cancer du rein de l’adulte. Rev Prat 1992; 42: 55-59.
[19]
Steiner G, Cairns P, Polascik TJ, Marshall F F, Epstein J I, Sidransky D et al. High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. Cancer Res. 1996; 56 (21): 5044-5046.
[20]
Chow W H, Devesa S S, Warren J L, Fraumeni Jr J F. Rising incidence of renal cell cancer in United States. JAMA 1999; 281 (17): 1628-1631.
[21]
Lightfoot N, Conlon M, Kreiger N, Bissett R, Desai M, Warde P et al. Impact of non-invasive imaging on increased inci- dental detection of renal cell cancer. Eur Urol 2000; 37: 521-527.
[22]
Bensalah K, Albiges L, Bernhard J C, Bigot P, Bodin T, Boissier R et al. Retracted: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020: prise en charge du cancer du rein. Prog Urol. 2018; 28 (12): S3-31.
[23]
Lecouteux A, Rigaud J, Glemain P, Le Normand L, Bouchot O, Karam G. Néphrectomie partielle de nécessité pour carcinome à cellules rénales: résultats oncologiques et fonctionnels. Prog urol. 2011; 21: 599-606.
[24]
Springer C, Hoda M R, Fajkovic H, Pini G, Mohammed N, Fornara P et al. Laparoscopic vs open partial nephrectomy for T1 renal tumours: evaluation of long- term oncological and functional outcomes in 340 patients. BJU Int. 2013; 111: 281-288.
[25]
Miller J C, Pien H H, Sahani D, Sorensen A G, Thrall J H. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97: 172-187.
[26]
Rini B I, Garcia J, Elson P, Wood L, Shah S, Stephenson A et al. The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery. Journal of Urology. 2012; 187 (5): 1548-1554.
[27]
Silberstein J L, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio C J et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery: FEASIBILITY AND EFFICACY OF NEOADJUVANT SUNITINIB BEFORE NEPHRON-SPARING SURGERY. BJU International. 2010; 106 (9): 1270-1276.
[28]
Karakiewicz P I, Suardi N, Jeldres C, Audet P, Ghosn P, Patard J J et al. Neoadjuvant Sutent Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. Eur Urol. 2008; 53 (4): 845848.
[29]
Huang D, Ding Y, Li Y, Luo W M, Zhang Z F, Snider J et al. Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma. Cancer Research. 2010; 70 (3): 1053-1062.
[30]
Khafaja S, Kourie HR, Matar D, Sader-Ghorra C, Kattan J. Kidney Cancer in Lebanon: a Specific Histological Distribution? Asian Pacific Journal of Cancer Prevention. 2015; 16 (1): 363365.
[31]
Bernhard J C, Pantuck AJ, Wallerand H, Crepel M, Ferrière J M, Bellec L, et al. Predictive factors foripsi lateral recurrence after nephron-sparing surgery in renal cell carcinoma. Eur Urol 2010; 57: 1080—1086.
[32]
Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007; 99: 296—300.
Browse journals by subject